Accelerating antibody discovery and design with artificial intelligence: Recent advances and prospects
G Bai, C Sun, Z Guo, Y Wang, X Zeng, Y Su… - Seminars in Cancer …, 2023 - Elsevier
Therapeutic antibodies are the largest class of biotherapeutics and have been successful in
treating human diseases. However, the design and discovery of antibody drugs remains …
treating human diseases. However, the design and discovery of antibody drugs remains …
Facts and hopes on chimeric cytokine agents for cancer immunotherapy
Cytokines are key mediators of immune responses that can modulate the antitumor activity
of immune cells. Cytokines have been explored as a promising cancer immunotherapy …
of immune cells. Cytokines have been explored as a promising cancer immunotherapy …
Engineering cytokines for cancer immunotherapy: a systematic review
Y Fu, R Tang, X Zhao - Frontiers in Immunology, 2023 - frontiersin.org
Cytokines are pivotal mediators of cell communication in the tumor microenvironment.
Multiple cytokines are involved in the host antitumor response, but the production and …
Multiple cytokines are involved in the host antitumor response, but the production and …
IL-2 based cancer immunotherapies: An evolving paradigm
Discovered over 4 decades ago in the supernatants of activated T cells, interleukin-2 (IL-2)
is a potent pleiotropic cytokine involved in the regulation of immune responses. It is required …
is a potent pleiotropic cytokine involved in the regulation of immune responses. It is required …
[HTML][HTML] The T-Cell Growth Factor Interleukin-2, Which Is Occasionally Targeted by Autoantibodies, Qualifies as Drug for the Treatment of Allergy, Autoimmunity, and …
PA Tauber, RB Stieger, B Kratzer… - International Archives of …, 2024 - ncbi.nlm.nih.gov
Abstract Interleukin (IL)-2 was originally characterized as an important T-cellular growth
factor but later on, turned out to be a pivotal homeostatic factor for the establishment and …
factor but later on, turned out to be a pivotal homeostatic factor for the establishment and …
An antibody against human interleukin-2 showing minimal binding to neonatal Fc receptor: potent anti-tumor activity and reduced systemic toxicity in mice
Y Lv, J Chen, C Wang, Z Jin, J Lou - European Journal of Pharmacology, 2024 - Elsevier
The anti-tumor efficacy of immune checkpoint inhibitors can be enhanced by combining
them with interleukin-2 (IL-2), which promotes the clonal expansion of antigen-activated …
them with interleukin-2 (IL-2), which promotes the clonal expansion of antigen-activated …
Clinical Immunology–Review Article
A Al Nasar Ahmed Sehgala Peter, TRB Stiegera… - Int Arch Allergy …, 2024 - karger.com
Abstract Interleukin (IL)-2 was originally characterized as an important T-cellular growth
factor but later on, turned out to be a pivotal homeostatic factor for the establishment and …
factor but later on, turned out to be a pivotal homeostatic factor for the establishment and …
[PDF][PDF] The effects of indigenous South African plant extracts (cotyledon c. orbiculata and tulbaghia. violacea) on triple negative breast cancer cells
M Alaouna - 2024 - wiredspace.wits.ac.za
This dissertation explored the potential therapeutic applications of water and methanol
extracts of C. orbiculata and Tulbaghia violacea, indigenous to Southern Africa, targeting …
extracts of C. orbiculata and Tulbaghia violacea, indigenous to Southern Africa, targeting …